Laurus Labs gets two observations from USFDA for its Visakhapatnam facilities

PTI New Delhi | Updated on June 14, 2019 Published on June 14, 2019

No data integrity issues were observed in the inspection

Drug firm Laurus Labs on Friday said the US health regulator has made two observations after the inspection of its Visakhapatnam facility in Andhra Pradesh.

The company has completed the United States Food and Drug Administration (USFDA) inspection of its active pharmaceutical ingredient (API) facilities in Units 1 and 3 at Parawada, Visakhapatnam, with two observations, Laurus Labs said in a filing to the BSE.

The observations are procedural in nature, it added.

“This is a regular surveillance audit by USFDA, and no data integrity issues were observed in the inspection,” Laurus Labs said.

The company, however, did not share any details about the observations made by the regulator.

Shares of Laurus Labs on Friday closed at Rs 338.70 on the BSE, up 0.82 per cent from its previous close.

Published on June 14, 2019
This article is closed for comments.
Please Email the Editor
You have read 1 out of 3 free articles for this week. For full access, please subscribe and get unlimited access to all sections.